Sichuan Xinsidun Pharmaceutial Co., Ltd.

This study investigates whether there are differences in the extent and rate of absorption between the test formulation dotenorfat tablets (Sichuan Xinston Pharmaceutical Co., Ltd., specification: 2mg) and the reference formulation dotenorfat tablets (trade name: URECE®, Fuji Pharmaceutical Co., Ltd., specification: 2mg) administered orally in fasting and postprandial states in healthy trial participants. The aim is to assess the bioequivalence of the two formulations under fasting and postprandial administration and to observe the safety of the test and reference formulations in healthy trial participants.

This study investigates whether there are differences in the extent and rate of absorption between the test formulation baricitinib tablets (Sichuan Xinston Pharmaceutical Co., Ltd., specification: 2mg) and the reference formulation baricitinib tablets (trade name: Eli Lilly Nederland B.V., specification: 2mg) administered orally to healthy participants after a single fasting oral dose. The study also aims to evaluate the bioequivalence of the test and reference formulations and to observe the safety of both formulations in healthy participants.

Main study objectives This study used dapagliflozin tablets (specification: 10 mg) produced by Sichuan Xinston Pharmaceutical Co., Ltd. as the test preparation and dapagliflozin tablets (trade name: Andatang/FORXIGA, specification: 10 mg) produced by AstraZeneca Pharmaceuticals LP as the reference preparation to investigate the pharmacokinetic parameters of the test preparation and the reference preparation in healthy subjects in the fasting and postprandial states, and to evaluate the bioequivalence of the two preparations. Secondary study objectives To observe the safety of the test preparation and the reference preparation in healthy subjects.